-
1
-
-
0000501656
-
Information theory and an extension of the maximum likelihood principle
-
Petrov BN and Csaki F eds, Academiai Kiado, Budapest
-
Akaike, H (1973) Information theory and an extension of the maximum likelihood principle, in Second International Symposium on Information Theory (Petrov BN and Csaki F eds) pp 267-281, Academiai Kiado, Budapest.
-
(1973)
Second International Symposium on Information Theory
, pp. 267-281
-
-
Akaike, H.1
-
2
-
-
0036020995
-
Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden
-
Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, and Ingelman-Sundberg M (2002) Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 12:375-383.
-
(2002)
Pharmacogenetics
, vol.12
, pp. 375-383
-
-
Aklillu, E.1
Herrlin, K.2
Gustafsson, L.L.3
Bertilsson, L.4
Ingelman-Sundberg, M.5
-
3
-
-
0026506140
-
Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin
-
Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, and Sjöqvist F (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 51:388-397.
-
(1992)
Clin Pharmacol Ther
, vol.51
, pp. 388-397
-
-
Bertilsson, L.1
Lou, Y.Q.2
Du, Y.L.3
Liu, Y.4
Kuang, T.Y.5
Liao, X.M.6
Wang, K.Y.7
Reviriego, J.8
Iselius, L.9
Sjöqvist, F.10
-
4
-
-
0013297123
-
-
Celexa., Forest Pharmaceuticals. St. Louis, MO
-
Celexa. (2009) Package insert. Forest Pharmaceuticals. St. Louis, MO.
-
(2009)
Package Insert
-
-
-
5
-
-
0029587180
-
Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
-
Chang M, Dahl ML, Tybring G, Götharson E, and Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics 5:358-363.
-
(1995)
Pharmacogenetics
, vol.5
, pp. 358-363
-
-
Chang, M.1
Dahl, M.L.2
Tybring, G.3
Götharson, E.4
Bertilsson, L.5
-
6
-
-
84908249654
-
Prediction of inter-individual variability in the pharmacokinetics of CYP2C19 substrates in humans
-
Chiba K, Shimizu K, Kato M, Nishibayashi T, Terada K, Izumo N, and Sugiyama Y (2014) Prediction of inter-individual variability in the pharmacokinetics of CYP2C19 substrates in humans. Drug Metab Pharmacokinet 29:379-386.
-
(2014)
Drug Metab Pharmacokinet
, vol.29
, pp. 379-386
-
-
Chiba, K.1
Shimizu, K.2
Kato, M.3
Nishibayashi, T.4
Terada, K.5
Izumo, N.6
Sugiyama, Y.7
-
7
-
-
79960115517
-
Sources of interindividual variability in IVIVE of clearance: An investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model
-
Cubitt HE, Yeo KR, Howgate EM, Rostami-Hodjegan A, and Barter ZE (2011) Sources of interindividual variability in IVIVE of clearance: An investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 41:623-638.
-
(2011)
Xenobiotica
, vol.41
, pp. 623-638
-
-
Cubitt, H.E.1
Yeo, K.R.2
Howgate, E.M.3
Rostami-Hodjegan, A.4
Barter, Z.E.5
-
8
-
-
0028860954
-
Genetic analysis of the S-mephenytoin polymorphism in a Chinese population
-
de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, and Zhou HH (1995) Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 58:404-411.
-
(1995)
Clin Pharmacol Ther
, vol.58
, pp. 404-411
-
-
De Morais, S.M.1
Goldstein, J.A.2
Xie, H.G.3
Huang, S.L.4
Lu, Y.Q.5
Xia, H.6
Xiao, Z.S.7
Ile, N.8
Zhou, H.H.9
-
9
-
-
0028260641
-
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
-
de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, and Goldstein JA (1994) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269:15419-15422.
-
(1994)
J Biol Chem
, vol.269
, pp. 15419-15422
-
-
De Morais, S.M.1
Wilkinson, G.R.2
Blaisdell, J.3
Nakamura, K.4
Meyer, U.A.5
Goldstein, J.A.6
-
10
-
-
80053574439
-
Association between CYP2C19∗17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients
-
de Vos A, van der Weide J, and Loovers HM (2011) Association between CYP2C19∗17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients. Pharmacogenomics J 11:359-367.
-
(2011)
Pharmacogenomics J
, vol.11
, pp. 359-367
-
-
De Vos, A.1
Van Der Weide, J.2
Loovers, H.M.3
-
11
-
-
34250663402
-
The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies-CYP2C9 and warfarin as an example
-
Dickinson GL, Lennard MS, Tucker GT, and Rostami-Hodjegan A (2007a) The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies-CYP2C9 and warfarin as an example. Br J Clin Pharmacol 64:14-26.
-
(2007)
Br J Clin Pharmacol
, vol.64
, pp. 14-26
-
-
Dickinson, G.L.1
Lennard, M.S.2
Tucker, G.T.3
Rostami-Hodjegan, A.4
-
12
-
-
33846450220
-
Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: Dextromethorphan as a model application
-
Dickinson GL, Rezaee S, Proctor NJ, Lennard MS, Tucker GT, and Rostami-Hodjegan A (2007b) Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application. J Clin Pharmacol 47:175-186.
-
(2007)
J Clin Pharmacol
, vol.47
, pp. 175-186
-
-
Dickinson, G.L.1
Rezaee, S.2
Proctor, N.J.3
Lennard, M.S.4
Tucker, G.T.5
Rostami-Hodjegan, A.6
-
13
-
-
79958854645
-
Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach
-
Duan JZ, Jackson AJ, and Zhao P (2011) Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach. J Clin Pharmacol 51:1087-1100.
-
(2011)
J Clin Pharmacol
, vol.51
, pp. 1087-1100
-
-
Duan, J.Z.1
Jackson, A.J.2
Zhao, P.3
-
14
-
-
33947603700
-
Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System
-
Dumaual C, Miao X, Daly TM, Bruckner C, Njau R, Fu DJ, Close-Kirkwood S, Bauer N, Watanabe N, and Hardenbol P, et al. (2007) Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. Pharmacogenomics 8:293-305.
-
(2007)
Pharmacogenomics
, vol.8
, pp. 293-305
-
-
Dumaual, C.1
Miao, X.2
Daly, T.M.3
Bruckner, C.4
Njau, R.5
Fu, D.J.6
Close-Kirkwood, S.7
Bauer, N.8
Watanabe, N.9
Hardenbol, P.10
-
15
-
-
0013297123
-
-
Eliglustat., Genzyme Corporation, Cambridge, MA
-
Eliglustat. (2014) package insert. Genzyme Corporation, Cambridge, MA.
-
(2014)
Package Insert
-
-
-
16
-
-
15444340367
-
A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
-
Ferguson RJ, De-Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, and Dayer P, et al. (1998) A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 284:356-361.
-
(1998)
J Pharmacol Exp Ther
, vol.284
, pp. 356-361
-
-
Ferguson, R.J.1
De-Morais, S.M.2
Benhamou, S.3
Bouchardy, C.4
Blaisdell, J.5
Ibeanu, G.6
Wilkinson, G.R.7
Sarich, T.C.8
Wright, J.M.9
Dayer, P.10
-
17
-
-
70749088207
-
Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram
-
Fudio S, Borobia AM, Piñana E, Ramírez E, Tabarés B, Guerra P, Carcas A, and Frías J (2010) Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. Eur J Pharmacol 626:200-204.
-
(2010)
Eur J Pharmacol
, vol.626
, pp. 200-204
-
-
Fudio, S.1
Borobia, A.M.2
Piñana, E.3
Ramírez, E.4
Tabarés, B.5
Guerra, P.6
Carcas, A.7
Frías, J.8
-
18
-
-
84866632585
-
CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers
-
Gawronska-Szklarz B, Adamiak-Giera U, Wyska E, Kurzawski M, Gornik W, Kaldonska M, and Drozdzik M (2012) CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Eur J Clin Pharmacol 68:1267-1274.
-
(2012)
Eur J Clin Pharmacol
, vol.68
, pp. 1267-1274
-
-
Gawronska-Szklarz, B.1
Adamiak-Giera, U.2
Wyska, E.3
Kurzawski, M.4
Gornik, W.5
Kaldonska, M.6
Drozdzik, M.7
-
19
-
-
0030904031
-
Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations
-
Goldstein JA, Ishizaki T, Chiba K, de-Morais SM, Bell D, Krahn PM, and Evans DA (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7:59-64.
-
(1997)
Pharmacogenetics
, vol.7
, pp. 59-64
-
-
Goldstein, J.A.1
Ishizaki, T.2
Chiba, K.3
De-Morais, S.M.4
Bell, D.5
Krahn, P.M.6
Evans, D.A.7
-
20
-
-
84877079740
-
In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates
-
Goutelle S, Bourguignon L, Bleyzac N, Berry J, Clavel-Grabit F, and Tod M (2013) In vivo quantitative prediction of the effect of gene polymorphisms and drug interactions on drug exposure for CYP2C19 substrates. AAPS J 15:415-426.
-
(2013)
AAPS J
, vol.15
, pp. 415-426
-
-
Goutelle, S.1
Bourguignon, L.2
Bleyzac, N.3
Berry, J.4
Clavel-Grabit, F.5
Tod, M.6
-
21
-
-
85027923345
-
The influence of CYP2C19∗2 and ∗17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting
-
Harmsze AM, van Werkum JW, Hackeng CM, Ruven HJ, Kelder JC, Bouman HJ, Breet NJ, Ten Berg JM, Klungel OH, and de Boer A, et al. (2012) The influence of CYP2C19∗2 and ∗17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics 22:169-175.
-
(2012)
Pharmacogenet Genomics
, vol.22
, pp. 169-175
-
-
Harmsze, A.M.1
Van Werkum, J.W.2
Hackeng, C.M.3
Ruven, H.J.4
Kelder, J.C.5
Bouman, H.J.6
Breet, N.J.7
Ten Berg, J.M.8
Klungel, O.H.9
De Boer, A.10
-
22
-
-
0036219836
-
CYP2C19 genotype and S-mephenytoin 49-hydroxylation phenotype in a Chinese Dai population
-
He N, Yan FX, Huang SL, Wang W, Xiao ZS, Liu ZQ, and Zhou HH (2002) CYP2C19 genotype and S-mephenytoin 49-hydroxylation phenotype in a Chinese Dai population. Eur J Clin Pharmacol 58:15-18.
-
(2002)
Eur J Clin Pharmacol
, vol.58
, pp. 15-18
-
-
He, N.1
Yan, F.X.2
Huang, S.L.3
Wang, W.4
Xiao, Z.S.5
Liu, Z.Q.6
Zhou, H.H.7
-
23
-
-
33745130722
-
Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability
-
Howgate EM, Rowland Yeo K, Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2006) Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica 36:473-497.
-
(2006)
Xenobiotica
, vol.36
, pp. 473-497
-
-
Howgate, E.M.1
Rowland, Y.K.2
Proctor, N.J.3
Tucker, G.T.4
Rostami-Hodjegan, A.5
-
24
-
-
0037403687
-
Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole
-
Hyland R, Jones BC, and Smith DA (2003) Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 31:540-547.
-
(2003)
Drug Metab Dispos
, vol.31
, pp. 540-547
-
-
Hyland, R.1
Jones, B.C.2
Smith, D.A.3
-
25
-
-
0022623877
-
Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co-regulated substrate, mephobarbital
-
Jacqz E, Hall SD, Branch RA, and Wilkinson GR (1986) Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital. Clin Pharmacol Ther 39:646-653.
-
(1986)
Clin Pharmacol Ther
, vol.39
, pp. 646-653
-
-
Jacqz, E.1
Hall, S.D.2
Branch, R.A.3
Wilkinson, G.R.4
-
26
-
-
67649392513
-
A framework for assessing interindividual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates
-
Jamei M, Dickinson GL, and Rostami-Hodjegan A (2009) A framework for assessing interindividual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet 24:53-75.
-
(2009)
Drug Metab Pharmacokinet
, vol.24
, pp. 53-75
-
-
Jamei, M.1
Dickinson, G.L.2
Rostami-Hodjegan, A.3
-
27
-
-
32044456194
-
Enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 49-hydroxymephenytoin in human plasma and urine by liquid chromatography/tandem mass spectrometry
-
Jansson B, Elsherbiny D, and Simonsson US (2006) Enantiospecific separation and quantitation of mephenytoin and its metabolites nirvanol and 49-hydroxymephenytoin in human plasma and urine by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 20:463-472.
-
(2006)
Rapid Commun Mass Spectrom
, vol.20
, pp. 463-472
-
-
Jansson, B.1
Elsherbiny, D.2
Simonsson, U.S.3
-
28
-
-
0031807369
-
Singledose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects
-
Joffe P, Larsen FS, Pedersen V, Ring-Larsen H, Aaes-Jørgensen T, and Sidhu J (1998) Singledose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol 54:237-242.
-
(1998)
Eur J Clin Pharmacol
, vol.54
, pp. 237-242
-
-
Joffe, P.1
Larsen, F.S.2
Pedersen, V.3
Ring-Larsen, H.4
Aaes-Jørgensen, T.5
Sidhu, J.6
-
29
-
-
67649407499
-
Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: Using in vitro data as an aid to assess study power
-
Johnson TN, Kerbusch T, Jones B, Tucker GT, Rostami-Hodjegan A, and Milligan PA (2009) Assessing the efficiency of mixed effects modelling in quantifying metabolism based drug-drug interactions: using in vitro data as an aid to assess study power. Pharm Stat 8:186-202.
-
(2009)
Pharm Stat
, vol.8
, pp. 186-202
-
-
Johnson, T.N.1
Kerbusch, T.2
Jones, B.3
Tucker, G.T.4
Rostami-Hodjegan, A.5
Milligan, P.A.6
-
30
-
-
0031845066
-
Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6
-
Ko JW, Desta Z, and Flockhart DA (1998) Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6. Drug Metab Dispos 26:775-778.
-
(1998)
Drug Metab Dispos
, vol.26
, pp. 775-778
-
-
Ko, J.W.1
Desta, Z.2
Flockhart, D.A.3
-
31
-
-
84896092716
-
MicroRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450
-
Lamba V, Ghodke Y, Guan W, and Tracy TS (2014) microRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450. Biochem Biophys Res Commun 445:404-411.
-
(2014)
Biochem Biophys Res Commun
, vol.445
, pp. 404-411
-
-
Lamba, V.1
Ghodke, Y.2
Guan, W.3
Tracy, T.S.4
-
32
-
-
0003981320
-
-
4th ed, Springer-Verlag, New York
-
Loève MM (1977) Probability Theory, 4th ed, Springer-Verlag, New York.
-
(1977)
Probability Theory
-
-
Loève, M.M.1
-
33
-
-
45749083522
-
Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- And third-generation Japanese populations: Comparison with Korean, Chinese, and Caucasian populations
-
Myrand SP, Sekiguchi K, Man MZ, Lin X, Tzeng RY, Teng CH, Hee B, Garrett M, Kikkawa H, and Lin CY, et al. (2008) Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- And third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 84:347-361.
-
(2008)
Clin Pharmacol Ther
, vol.84
, pp. 347-361
-
-
Myrand, S.P.1
Sekiguchi, K.2
Man, M.Z.3
Lin, X.4
Tzeng, R.Y.5
Teng, C.H.6
Hee, B.7
Garrett, M.8
Kikkawa, H.9
Lin, C.Y.10
-
34
-
-
0020425640
-
Kinetics of citalopram in man; plasma levels in patients
-
Overø FK (1982) Kinetics of citalopram in man; plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry 6:311-318.
-
(1982)
Prog Neuropsychopharmacol Biol Psychiatry
, vol.6
, pp. 311-318
-
-
Overoø, F.K.1
-
35
-
-
4444278991
-
The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes
-
Parkinson A, Mudra DR, Johnson C, Dwyer A, and Carroll KM (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193-209.
-
(2004)
Toxicol Appl Pharmacol
, vol.199
, pp. 193-209
-
-
Parkinson, A.1
Mudra, D.R.2
Johnson, C.3
Dwyer, A.4
Carroll, K.M.5
-
36
-
-
0030462277
-
S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians
-
Persson I, Aklillu E, Rodrigues F, Bertilsson L, and Ingelman-Sundberg M (1996) S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 6:521-526.
-
(1996)
Pharmacogenetics
, vol.6
, pp. 521-526
-
-
Persson, I.1
Aklillu, E.2
Rodrigues, F.3
Bertilsson, L.4
Ingelman-Sundberg, M.5
-
37
-
-
0013297123
-
-
Protonix., Wyeth Pharmaceuticals, Philadelphia, PA
-
Protonix. (2000) Package insert. Wyeth Pharmaceuticals, Philadelphia, PA.
-
(2000)
Package Insert
-
-
-
38
-
-
42449124602
-
The "albumin effect" and in vitro-in vivo extrapolation: Sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9
-
Rowland A, Elliot DJ, Knights KM, Mackenzie PI, and Miners JO (2008) The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Dispos 36:870-877.
-
(2008)
Drug Metab Dispos
, vol.36
, pp. 870-877
-
-
Rowland, A.1
Elliot, D.J.2
Knights, K.M.3
Mackenzie, P.I.4
Miners, J.O.5
-
39
-
-
38349110295
-
Impact of the ultrarapid CYP2C19∗17 allele on serum concentration of escitalopram in psychiatric patients
-
Rudberg I, Mohebi B, Hermann M, Refsum H, and Molden E (2008) Impact of the ultrarapid CYP2C19∗17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 83:322-327.
-
(2008)
Clin Pharmacol Ther
, vol.83
, pp. 322-327
-
-
Rudberg, I.1
Mohebi, B.2
Hermann, M.3
Refsum, H.4
Molden, E.5
-
40
-
-
0024336503
-
S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin
-
Sanz EJ, Villén T, Alm C, and Bertilsson L (1989) S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 45:495-499.
-
(1989)
Clin Pharmacol Ther
, vol.45
, pp. 495-499
-
-
Sanz, E.J.1
Villén, T.2
Alm, C.3
Bertilsson, L.4
-
41
-
-
79960613122
-
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy
-
Clinical Pharmacogenetics Implementation Consortium
-
Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, and Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium (2011) Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 90:328-332.
-
(2011)
Clin Pharmacol Ther
, vol.90
, pp. 328-332
-
-
Scott, S.A.1
Sangkuhl, K.2
Gardner, E.E.3
Stein, C.M.4
Hulot, J.S.5
Johnson, J.A.6
Roden, D.M.7
Klein, T.E.8
Shuldiner, A.R.9
-
42
-
-
30344457586
-
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
-
Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, and Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113.
-
(2006)
Clin Pharmacol Ther
, vol.79
, pp. 103-113
-
-
Sim, S.C.1
Risinger, C.2
Dahl, M.L.3
Aklillu, E.4
Christensen, M.5
Bertilsson, L.6
Ingelman-Sundberg, M.7
-
43
-
-
6344285930
-
Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population
-
Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, and Dawson EP (2004) Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5:895-931.
-
(2004)
Pharmacogenomics
, vol.5
, pp. 895-931
-
-
Solus, J.F.1
Arietta, B.J.2
Harris, J.R.3
Sexton, D.P.4
Steward, J.Q.5
McMunn, C.6
Ihrie, P.7
Mehall, J.M.8
Edwards, T.L.9
Dawson, E.P.10
-
44
-
-
2042431033
-
Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population
-
Sviri S, Shpizen S, Leitersdorf E, Levy M, and Caraco Y (1999) Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population. Clin Pharmacol Ther 65:275-282.
-
(1999)
Clin Pharmacol Ther
, vol.65
, pp. 275-282
-
-
Sviri, S.1
Shpizen, S.2
Leitersdorf, E.3
Levy, M.4
Caraco, Y.5
-
45
-
-
0026934962
-
A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio
-
Tybring G and Bertilsson L (1992) A methodological investigation on the estimation of the S-mephenytoin hydroxylation phenotype using the urinary S/R ratio. Pharmacogenetics 2:241-243.
-
(1992)
Pharmacogenetics
, vol.2
, pp. 241-243
-
-
Tybring, G.1
Bertilsson, L.2
-
46
-
-
0016174577
-
Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes
-
Van-der-Hoeven TA and Coon MJ (1974) Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate-cytochrome P-450 reductase from rabbit liver microsomes. J Biol Chem 249:6302-6310.
-
(1974)
J Biol Chem
, vol.249
, pp. 6302-6310
-
-
Van-Der-Hoeven, T.A.1
Coon, M.J.2
-
47
-
-
80053611043
-
Functional evaluation of genetic and environmental regulators of p450 mRNA levels
-
Wang D, Jiang Z, Shen Z, Wang H, Wang B, Shou W, Zheng H, Chu X, Shi J, and Huang W (2011a) Functional evaluation of genetic and environmental regulators of p450 mRNA levels. PLoS One 6:e24900.
-
(2011)
PLoS One
, vol.6
, pp. e24900
-
-
Wang, D.1
Jiang, Z.2
Shen, Z.3
Wang, H.4
Wang, B.5
Shou, W.6
Zheng, H.7
Chu, X.8
Shi, J.9
Huang, W.10
-
48
-
-
79955036726
-
Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 49-hydroxylation and omeprazole 59-hydroxylation
-
Wang H, An N, Wang H, Gao Y, Liu D, Bian T, Zhu J, and Chen C (2011b) Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 49-hydroxylation and omeprazole 59-hydroxylation. Drug Metab Dispos 39:830-837.
-
(2011)
Drug Metab Dispos
, vol.39
, pp. 830-837
-
-
Wang, H.1
An, N.2
Wang, H.3
Gao, Y.4
Liu, D.5
Bian, T.6
Zhu, J.7
Chen, C.8
-
49
-
-
0021927630
-
Phenotypic differences in mephenytoin pharmacokinetics in normal subjects
-
Wedlund PJ, Aslanian WS, Jacqz E, McAllister CB, Branch RA, and Wilkinson GR (1985) Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. J Pharmacol Exp Ther 234:662-669.
-
(1985)
J Pharmacol Exp Ther
, vol.234
, pp. 662-669
-
-
Wedlund, P.J.1
Aslanian, W.S.2
Jacqz, E.3
McAllister, C.B.4
Branch, R.A.5
Wilkinson, G.R.6
-
50
-
-
0021684926
-
Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism
-
Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, and Branch RA (1984) Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 36:773-780.
-
(1984)
Clin Pharmacol Ther
, vol.36
, pp. 773-780
-
-
Wedlund, P.J.1
Aslanian, W.S.2
McAllister, C.B.3
Wilkinson, G.R.4
Branch, R.A.5
-
51
-
-
58849130987
-
CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole
-
Weiss J, Ten-Hoevel MM, Burhenne J, Walter-Sack I, Hoffmann MM, Rengelshausen J, Haefeli WE, and Mikus G (2009) CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J Clin Pharmacol 49:196-204.
-
(2009)
J Clin Pharmacol
, vol.49
, pp. 196-204
-
-
Weiss, J.1
Ten-Hoevel, M.M.2
Burhenne, J.3
Walter-Sack, I.4
Hoffmann, M.M.5
Rengelshausen, J.6
Haefeli, W.E.7
Mikus, G.8
-
52
-
-
32944471001
-
So many studies, too few subjects: Establishing functional relevance of genetic polymorphisms on pharmacokinetics
-
Williams JA, Johnson K, Paulauskis J, and Cook J (2006) So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics. J Clin Pharmacol 46:258-264.
-
(2006)
J Clin Pharmacol
, vol.46
, pp. 258-264
-
-
Williams, J.A.1
Johnson, K.2
Paulauskis, J.3
Cook, J.4
-
53
-
-
84894526589
-
Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: Application to predict drug/genetic interactions
-
Wu F, Gaohua L, Zhao P, Jamei M, Huang SM, Bashaw ED, and Lee SC (2014) Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: Application to predict drug/genetic interactions. Pharm Res 31:1919-1929.
-
(2014)
Pharm Res
, vol.31
, pp. 1919-1929
-
-
Wu, F.1
Gaohua, L.2
Zhao, P.3
Jamei, M.4
Huang, S.M.5
Bashaw, E.D.6
Lee, S.C.7
-
54
-
-
8244249473
-
Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele
-
Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, and Xu ZH, et al. (1997) Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 281:604-609.
-
(1997)
J Pharmacol Exp Ther
, vol.281
, pp. 604-609
-
-
Xiao, Z.S.1
Goldstein, J.A.2
Xie, H.G.3
Blaisdell, J.4
Wang, W.5
Jiang, C.H.6
Yan, F.X.7
He, N.8
Huang, S.L.9
Xu, Z.H.10
-
55
-
-
84888613878
-
CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling
-
Xu C, Quinney SK, Guo Y, Hall SD, Li L, and Desta Z (2013) CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling. Drug Metab Dispos 41:2004-2011.
-
(2013)
Drug Metab Dispos
, vol.41
, pp. 2004-2011
-
-
Xu, C.1
Quinney, S.K.2
Guo, Y.3
Hall, S.D.4
Li, L.5
Desta, Z.6
-
56
-
-
84878015548
-
Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure
-
Yeo KR, Kenny JR, and Rostami-Hodjegan A (2013) Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. Eur J Clin Pharmacol 69:1311-1320.
-
(2013)
Eur J Clin Pharmacol
, vol.69
, pp. 1311-1320
-
-
Yeo, K.R.1
Kenny, J.R.2
Rostami-Hodjegan, A.3
-
57
-
-
33746906715
-
Phenotypegenotype relationship and clinical effects of citalopram in Chinese patients
-
Yin OQ, Wing YK, Cheung Y, Wang ZJ, Lam SL, Chiu HF, and Chow MS (2006) Phenotypegenotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol 26:367-372.
-
(2006)
J Clin Psychopharmacol
, vol.26
, pp. 367-372
-
-
Yin, O.Q.1
Wing, Y.K.2
Cheung, Y.3
Wang, Z.J.4
Lam, S.L.5
Chiu, H.F.6
Chow, M.S.7
-
58
-
-
0141569602
-
Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19
-
Yu BN, Chen GL, He N, Ouyang DS, Chen XP, Liu ZQ, and Zhou HH (2003) Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos 31:1255-1259.
-
(2003)
Drug Metab Dispos
, vol.31
, pp. 1255-1259
-
-
Yu, B.N.1
Chen, G.L.2
He, N.3
Ouyang, D.S.4
Chen, X.P.5
Liu, Z.Q.6
Zhou, H.H.7
-
59
-
-
0025970955
-
Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies
-
Zhang Y, Blouin RA, McNamara PJ, Steinmetz J, and Wedlund PJ (1991) Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 31:350-352.
-
(1991)
Br J Clin Pharmacol
, vol.31
, pp. 350-352
-
-
Zhang, Y.1
Blouin, R.A.2
McNamara, P.J.3
Steinmetz, J.4
Wedlund, P.J.5
|